AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SERA · NASDAQ · Medical - Diagnostics & Research

Sera

Develops blood tests and predictive analytics for earlier assessment of spontaneous preterm-birth risk.

$2.00

After-hours close−0.06 (−3.15%)

At close$2.07(+1.72%)

Something off on this page? Send us feedback.

Profile

Sera Prognostics, Inc.SERAHealth Care

Develops and commercializes the PreTRM blood test for assessing spontaneous preterm-birth risk in singleton pregnancies. Its pregnancy-focused platform combines proteomics, bioinformatics, clinical testing, data, and economic analysis; commercial adoption depends on payer coverage and clinical use.

PreTRM is a non-invasive blood test for assessing spontaneous preterm-birth risk in singleton pregnancies. It is the first commercial product within a pregnancy-focused pipeline of biomarker tests and predictive analytic products.

The platform combines proteomics, bioinformatics, clinical testing, data, and economic analysis to support pregnancy care. Its stated mission is to give pregnant women, physicians, and payers actionable information for maternal and neonatal health. Operations include a CLIA-certified laboratory in Salt Lake City.

Commercial execution centers on payer discussions and converting clinical evidence into broader adoption and coverage. Payer coverage and clinical use shape the commercial path.

Company facts

CEOZhenya Lindgardt

ListedJul 15, 2021

ExchangeNASDAQ

HeadquartersSalt Lake City, UT

CountryUnited States

Employees64

CIK0001534969

ISINUS81749D1072

Key statistics

Market cap$79.1M

EPS (ttm)−$0.6700

P/E (ttm)−3.09

ROE-46.7%

P/B1.76

P/S1,129.36

Dividend yield—

Beta0.94vs XLV 0.72

Year to date −31.2% · Average volume (30d) 33.8K

Analysts

Price target, next 12 months$6.00+189.9%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy4 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $2.07

High$6.00+189.9%

Median$6.00+189.9%

Low$6.00+189.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Jun 4, 2026	Craig-Hallum	Target	$6
Dec 14, 2025	Jefferies	Target	$5

Earnings

EPS

Estimate−$0.14

ReportedDue Nov 12, 2026

Revenue

Estimate$75.0K

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.15	−$0.18	−16.7%	$71.4K	$30.0K	−58.0%	−0.50%
May 6, 2026Q1 FY26	−$0.16	−$0.17	−6.3%	$66.7K	$14.0K	−79.0%	+6.08%
Mar 18, 2026Q4 FY25	−$0.17	−$0.16	+5.9%	$31.8K	$10.0K	−68.5%	−6.28%
Nov 13, 2025Q3 FY25	−$0.19	−$0.16	+15.8%	$50.4K	$16.0K	−68.2%	+0.34%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$38.0K	$17.0K	$16.0K	$10.0K	$14.0K	$30.0K
Gross profit	−$2.0K	−$24.0K	−$25.0K	−$32.0K	−$28.0K	−$20.0K
Operating income	−$9.3M	−$9.3M	−$9.0M	−$9.0M	−$9.4M	−$10.0M
Net income	−$8.2M	−$8.0M	−$7.8M	−$7.9M	−$8.4M	−$9.1M
Diluted EPS	−$0.20	−$0.16	−$0.16	−$0.16	−$0.17	−$0.18
Gross margin	-5.3%	-141.2%	-156.3%	-320.0%	-200.0%	-66.7%
Operating margin	-24,342.1%	-54,823.5%	-56,125.0%	-89,540.0%	-66,857.1%	-33,346.7%

Fiscal years (4-quarter sums)FY21 $82.0K · FY22 $268.0K · FY23 $306.0K · FY24 $77.0K · FY25 $81.0K

Balance sheet, Jun 30, 2026Cash & short-term investments $46.4M · Total debt $3.0M · Total assets $86.7M · Shareholders' equity $59.4M

Dividends

No dividends on record.

Ownership

Institutions 52.49%20.04M sharesInsiders 8.18%3.12M sharesOther 39.33%15.02M shares

Shares outstanding 38.19M · Float 27.47M · 71.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Baker Bros. Advisors LP	5.50M	14.40%	13F	May 15, 2026
Whetstone Capital Advisors, LLC	3.31M	8.60%	13G	May 1, 2026
Aberdeen Group plc	2.75M	7.21%	13G	Jul 15, 2026
Chione Ltd.	2.61M	7.60%	13D	Feb 14, 2025
Abrdn PLC	2.55M	6.68%	13F	Apr 29, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 11, 2026	Benjamin Jackson	officer: General Counsel	−2,179	$2.01
Jun 11, 2026	Tiffany Eul Davis Inglis	officer: Chief Medical Officer	−362	$2.01
Jun 11, 2026	Zhenya Lindgardt	director, officer: Chief Executive Officer	−6,990	$2.01
Jun 11, 2026	Austin Aerts	officer: Chief Financial Officer	−2,037	$2.01
Jun 11, 2026	Dyaarl Lee Jr. Anderson	officer: Chief Commercial Officer	−4,739	$2.01